Results 1 to 10 of about 74,008 (160)
Janus Kinase inhibitors in the treatment of large vessel vasculitis: a systematic review and meta-analysis [PDF]
This meta-analysis evaluates Janus Kinase (JAK) inhibitors’ efficacy and safety in large vessel vasculitis (LVV), encompassing Giant Cell Arteritis (GCA) and Takayasu’s Arteritis (TAK).
Bai Yang, Wang Zhe, Zhang Chunling
doaj +2 more sources
Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
Janus kinase inhibitors, also known as JAK inhibitors, JAKinibs or JAKi, are a new group of disease-modifying drugs. They work by inhibiting enzymes involved in the transmission of information from receptors located in the cell membrane to the cell ...
Izabella Ryguła +2 more
doaj +3 more sources
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives [PDF]
Karen Ly,1 Kristen M Beck,1 Mary P Smith,1 Ana-Maria Orbai,2 Wilson Liao11Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USACorrespondence ...
Ly K +4 more
doaj +2 more sources
Janus kinase inhibitors - their current applications and future prospects [PDF]
Janus kinase inhibitors are a group of drugs that provide an alternative to conventional therapy for numerous diseases. The most studied drug of this group is tofacitinib.
Natalia Wierzbowska +4 more
doaj +1 more source
Itch and Janus Kinase Inhibitors
Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways.
Yujin Han +4 more
doaj +1 more source
Intraocular infections following biologicals and Janus Kinase inhibitors [PDF]
Parthopratim Dutta Majumder +1 more
doaj +2 more sources
Recent studies have gradually elucidated the pathogenesis of inflammatory bowel disease; thus, the Janus kinase (JAK)-signal transducers and activators of transcription pathway are strongly involved in the pathophysiology of inflammatory bowel disease ...
Hiroshi Nakase
doaj +1 more source
Background: Coronavirus disease 2019 (COVID-19), it is an infectious respiratory disease caused by SARS corona virus 2 (SARS CoV-2). There are several reports of using JAK (Janus kinase)-inhibitors in persons with COVID-19 and the use of these decreased ...
Shankar Gharge +3 more
doaj +1 more source
Janus kinase inhibitors: between prescription authorization and reimbursability
Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria ...
F.R. Spinelli +5 more
doaj +1 more source
JAK3 as an emerging target for topical treatment of inflammatory skin diseases [PDF]
The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia ...
Alves de Medeiros, Ana +5 more
core +6 more sources

